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Diabetes is not a predictor of outcome for carotid
revascularization with stenting as it may be for
carotid endarterectomy
Gianbattista Parlani, MD,a Paola De Rango, MD, PhD,a Enrico Cieri, MD, PhD,a
Fabio Verzini, MD, PhD,a Giuseppe Giordano, MD,a Gioele Simonte, MD,a Giacomo Isernia, MD,a and
Piergiorgio Cao, MD, FRCS,b Perugia and Rome, Italy
Background: Diabetes is prevalent in most patients undergoing carotid revascularization and is suggested as a marker of
poor outcome after carotid endarterectomy (CEA). Data on outcome of diabetic patients undergoing carotid artery
stenting (CAS) are limited. The aim of this study was to investigate early and 6-year outcomes of diabetic patients
undergoing carotid revascularization with CAS and CEA.
Methods: The database of patients undergoing carotid revascularization for primary carotid stenosis was queried from
2001 to 2009. Diabetic patients were defined as those with established diagnosis and/or receiving oral hypoglycemic or
insulin therapy.Multivariate and Kaplan-Meier analyses, stratified by type of treatment, were performed on perioperative
(30 days) and late outcomes.
Results: A total of 2196 procedures, 1116 by CEA and 1080 by CAS (29% female, mean age 71.3 years), were reviewed.
Diabetes was prevalent in 630 (28.7%). Diabetic patients were younger (P< .0001) and frequently had hypertension (P
.018) or coronary disease (P  .019). Perioperative stroke/death rate was 2.7% (17/630) in diabetic patients vs 2.3%
(36/1566) in nondiabetic, (P .64); the rate was 3.4% in diabetic CEA group and 2.1% in diabetic CAS group (P .46).
Atmultivariate analyses, diabetes was a predictor of perioperative stroke/death in the CEA group (odds ratio [OR], 2.83;
95% confidence interval [CI], 1.05-7.61; P  .04) but not in the CAS group (P  .72). Six-year survival was 76.0% in
diabetics and 80.8% in nondiabetics (P .15). Six-year late stroke estimates were 3.2% in diabetic and 4.6% in nondiabetic
patients (P  .90). The 6-year risk of restenosis was similar (4.6% % vs 4.2%) in diabetic and nondiabetic patients (P 
.56). Survival, late stroke, and restenosis rates between diabetics and nondiabetics were similar in CAS and CEA groups.
Conclusions: Diabetic patients are not at greater risk of perioperative morbidity and mortality or late stroke after CAS,
however, the perioperative risk can be higher after CEA. This may help in selecting the appropriate technique for carotid
revascularization in patients best suited for the type of procedure. (J Vasc Surg 2012;55:79-89.)
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cCarotid artery stenting (CAS) has been recently en-
dorsed by international guidelines as a valid alternative to
carotid endarterectomy (CEA) for treatment of carotid
stenosis in subgroups of patients less suitable or at higher
risks for CEA.1 One of these subgroups might be the
diabetic population. Diabetes has been suggested as a
marker of higher surgical/operative risk during open vas-
cular procedures.2-5 Specifically, a number of authors sug-
gested that due to increased perioperative risks of stroke
and death during CEA, the benefit of the procedure in
stroke prevention might be decreased in this subgroup of
patients with carotid stenosis. However, there is no uni-
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doi:10.1016/j.jvs.2011.07.080orm consensus, but there are conflicting results.6 The
imited evidence available today seems to suggest that
iabetes is not risky for CAS procedure, nevertheless, data
n outcome of diabetic patients after CAS are limited.
urthermore, since the overall cardiovascular morbidity is
ncreased in diabetic patients, the long-term benefit of
arotid revascularization (whichever the procedure) may be
xcluded by an excessive mortality and stroke rate.
The aim of this study was to investigate perioperative
nd 6-year outcomes of diabetic vs nondiabetic patients
ndergoing CAS and those undergoing CEA in a single
enter experience.
ETHODS
Methodology was detailed in a previous study on the
ame cohort of patients.7 With respect to the original
ohort, follow-up was updated and six patients in whom no
ccurate information could be retrieved for the purpose of
his study were excluded.7 Briefly, a database of patients
ndergoing carotid revascularization at a single vascular
urgical center from January 2001 to March 2009 was
ueried for all patients undergoing CEA and CAS for
ignificant primary atherosclerotic occlusive disease. Vessels
reated for intimal hyperplasia, recurrent atherosclerotic
arotid stenosis, and bypass grafts were excluded. All pa-
ients had either 60% symptomatic or 70% asymptom-
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January 201280 Parlani et alatic carotid stenosis and were treated by surgeons. The
revascularization treatment choice (CAS/CEA) was left to
the discretion of the treating surgeon and was based on
general guidelines and team center experience according to
morphologic and clinical data indicating best suitability and
lower periprocedural risk for CAS and CEA. Criteria were
detailed previously.7,8 Usually, patients with unfavorable
aortic arch anatomy, severe peripheral vascular disease pre-
cluding femoral access, or extremely tortuous carotid anat-
omy were excluded from CAS. Similarly, old age, unstable
plaque, known allergies to aspirin, clopidogrel, or contrast
media, and renal insufficiency were considered exclusion
criteria for CAS. High-neck carotid bifurcation and long
carotid lesions as well as obesity and ongoing double anti-
platelet were relative contraindications for CEA.7
To avoid bias due to the learning curve effect of the
operators, the first 195 CAS performed within the training
phase (2001-2003) were excluded from the study.8 In our
center, with increasing experience, the number of CAS
increased over time allowing CEA to be used for fewer and
more complex cases (eg, acute stroke, unstable plaque, etc.)
in recent years. Therefore, CEAs performed in the last 2
years (2008-2009), when higher-risk selection criteria were
applied, were excluded from the present analysis to avoid
possible overestimated risk in CEA.
Neurologic symptoms were evaluated by a team of
neurologists who documented the presence, type, and se-
verity (National Institutes ofHealth [NIH] Stroke Scale) of
the event. Patients were defined as symptomatic when
ipsilateral hemispheric or retinal symptoms occurred within
6 months from the procedure. Stroke was defined as any
new hemispheric or retinal neurologic event persisting24
hours and classified as fatal, disabling (modified Rankin
Score  3), or nondisabling (modified Rankin Score  3).
The degree and characteristics of carotid stenosis were
assessed with Duplex ultrasound by experienced operators
who defined plaque characteristics and vessel measure-
ments as previously validated against angiography as a gold
standard technique.7 Contrast enhanced computed to-
mography (CTA) or, seldom, magnetic resonance (MR) of
carotid vessels was performed selectively in case of uncer-
tainty at ultrasound examination. Angiography was exclu-
sively applied during CAS procedure. Cerebral CT scan was
used in symptomatic patients to assess the extent of recent
lesions if any.
For carotid stenting, the patient was given aspirin (125-
325 mg once daily) in addition to clopidogrel (75 mg once
daily) or ticlopidine (250 mg twice daily) beginning 3 days
before the procedure.When clopidogrel therapy started3
days before CAS a 300-mg loading dose was administered 6
to 12 hours before the procedure. After the stenting pro-
cedure, clopidogrel was continued for 1 month and aspirin
was continued lifelong. All patients received an intravenous
heparin bolus (100 U/kg) to achieve systemic anticoagu-
lation during the carotid intervention. Carotid stenting was
performed following a standardized protocol in an endo-
vascular room equipped with a high quality fixed imaging
system (Axiom Artus FA, Siemens, Berlin, Germany). Per- butaneous transfemoral or transbrachial approaches under
ocal anesthesia were used for selective engagement of the
arget carotid artery. Minimal or no sedation was used
uring the procedure and neurologic status was continu-
usly monitored. Variable models of cerebral protection
evices (CPD) and carotid stents (open cell, close cell, or
ybrid configuration; tapered or straight) were employed in
ll procedures. The choice of specific material depended on
essel anatomy and lesion characteristics. Angioplasty was
erformed with a 5- to 6-mm diameter balloon. Closure
evices for the access control have been used since 2006.
For CEA, patients were usually maintained on aspirin
herapy. CEA was performed under local or general anes-
hesia with selective use of shunt. Both Dacron patch
ngioplasty and eversion endarterectomy (and exception-
lly, primary closure) were performed.
Patients scheduled for CAS/CEA with antiplatelet in-
olerance or already under ticlopidine (250 mg twice daily)
r under anticoagulation for coexisting medical comorbidi-
ies, continued to receive their baseline therapy at the usual
ose. Written consent was obtained from all patients before
evascularization.
Patients after both CEA and CAS were followed by
uplex ultrasound scan at 6 months, 12 months, and yearly
hereafter, and symptoms status was assessed. Carotid re-
tenosis was set at50% using ultrasound criteria.9 Patients
ere instructed to report any new neurologic symptoms
ccurring after hospital discharge. In case of neurologic
ymptoms or uncertainty occurring anytime after the pro-
edure, the patients were evaluated by a certified indepen-
ent neurologist expert in vascular disease.
Outcome measures and definitions. Primary out-
ome was the combined risk of any stroke or death within
0 days (perioperative). Secondary end points were the rate
f stroke, death, and restenosis at 6 years after the proce-
ure.
The exposure variable for this study was the presence of
iabetes mellitus at the time of carotid procedure. Diabetic
atients were defined as those with established diagnosis
nd/or receiving oral hypoglycemic or insulin therapy.
Coronary artery disease was defined as a history of
ngina pectoris, myocardial infarction (MI), congestive
eart disease, or prior coronary artery revascularizations.
estenosis was defined as the development of50% steno-
is. A major adverse clinical event (MACE) was defined as
ny stroke or MI or death. Any death, stroke, or MI 30
ays from the procedure was considered procedure-related.
erioperative was defined as a stroke, death, or any event
ccurring during hospital admission and 30 days post-
rocedure.
Statistical analysis. Analysis of data was by treatment
ctually received. Measured values are reported
s percentages or means standard deviations (SDs). Rates
or comorbidities, complications, and 30-day outcomes
ere compared between patients with and without diabetes
y 2 test.
Univariate analysis was used to quantify the association
etween each binary clinical variable and adverse event
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Volume 55, Number 1 Parlani et al 81outcome. Potential confounding and selection biases were
addressed by analyzing the rate of the primary outcome
(any stroke or death within 30 days) with multivariate
analyses after using backwards elimination methods assum-
ing diabetes as a covariate. The fit of the model was assessed
with the Hosmer and Lemeshow goodness-of-fit test,
where a P value less than .05 indicated an ill-fit model.10
The following variables were included in the model:
diabetes, treatment (CAS, CEA), age, gender, preoperative
symptoms, contralateral occlusion, coronary disease, pe-
ripheral artery disease, hypertension, on statin therapy,
complex plaque, and use of aspirin. Since patients under
insulin represented a subgroup within the diabetic popula-
tion leading to potential overlapping data, insulin use was
tested in separate repeated models.
Survival, restenosis, and stroke-free rates were calcu-
lated using Kaplan-Meier analysis to compensate for patient
dropouts and are reported using the current Society for
Vascular Surgery (SVS) criteria.11 Standard errors (SE) are
reported in Kaplan-Meier analyses and curves are displayed
up to a value of SE 0.10. The log-rank test was used to
determine survival differences between patients with and
without diabetes.
Associations between diabetes and covariates with
long-term outcome measures (death, stroke, and resteno-
sis) were assessed by Cox regression analyses by including
time-dependent interaction of each covariate with survival
time.
To account for specific covariates in each CAS or CEA
technique, subgroup analyses comparing diabetic vs non-
diabetic patients for periprocedural and late outcomes were
performed in models stratified by procedure.
A value of P  .05 was considered statistically signifi-
cant for all measurements. SPSS/PC version 13.00 Win
package (SPSS for Windows, SPSS, Inc., Chicago, Ill) was
used for all data analyses.
RESULTS
Over the study period a total of 2196 interventions for
primary carotid stenosis were performed in 2007 patients:
1080 by CAS (in 992 patients) and 1116 by CEA (in 1015
patients). There were 1558 males and 638 females; mean
age was 71.3 years (range 46-92). Six hundred eighty-four
(31.1%) were symptomatic and 1512 were asymptomatic
carotid stenosis. General anesthesia was employed in 594
CEA procedures.
Six hundred thirty procedures were performed in dia-
betic patients (28.7%), 150 of these were on insulin.
Demographic and baseline characteristics for diabetic
and nondiabetic populations are displayed in Tables I and
II.
Diabetes was more common in CAS than in CEA
patients (30.7% vs 26.7%, P .038). Diabetic patients were
younger (70.16  7.2 vs 71.75  7.7 years; P  .0001)
andmore likely to have a history of coronary disease (35.2%
vs 30.1%, P .019) or hypertension (84.6% vs 80.3%, P
.018) with respect to nondiabetic populations. There were uo substantial imbalances in the distribution of other fac-
ors.
Periprocedural outcomes. The 30-day (periproce-
ural) risk of stroke or death in overall populations was
.4% (53/2.196) with no significant differences in rates
etween the two procedures: 2.8% (30/1080) in CAS and
.1% (23/1116) in CEA (P  .33).
Periprocedural outcome measures in diabetics com-
ared with nondiabetics by CAS and CEA procedure are
eported in Fig 1. There were no significant differences in
eriprocedural risk of stroke or death between the two
roups: 2.7% (17/630) in diabetics vs 2.3% (36/1566) in
ondiabetics; P  .64.
Any perioperative MACE (including any stroke, death,
nd MI) occurred in 2.9% of diabetics and 2.6% of nondia-
etics (P  .662). Rates of MI, transient ischemic attack
TIA), and cranial nerve injuries were also evenly distributed.
eck hematoma in the CEA population wasmore frequent in
he diabetic group (3.0% vs 1.1%, P .03) (Fig 1).
At univariate analysis, symptomatic stenosis was associ-
ted with increased risk of perioperative stroke and death:
.5% in symptomatic vs 1.9% in asymptomatic; odds ratio
OR), 1.86; 95% confidence interval (CI), 1.07 to 3.21;
 .034 (Table III). Patients under insulin showed dou-
led risk (4.7% vs 2.2%) with respect to the others, but the
ifference did not achieve statistical relevance (P  .09).
owever, the difference was significant in the subgroup of
EA patients (6.5% vs 1.7%, P  .017; OR, 3.93; 95% CI,
.42-10.92) but not in CAS patients (2.7% vs 2.8%, P 1).
here were no other factors associated with stroke and
eath in the CEA group, while the use of statin was
ssociated with outcome in the CAS group (P  .014)
Table IV).
At multivariate analysis, using backward stepwise
ethod to select among potentially relevant predictors of
erioperative stroke and death, age (P  .088), contralat-
ral occlusion (P .053), and use of statin (P .032) were
etained in the last step of the model. However, only the
able I. Baseline characteristics in 2196 patients
Diabetes
(n  630)
No diabetes
(n  1566)
P valueN (%) N (%)
ge, years (SD) 70.16 (7.2) 71.75 (7.7) .0001
emales 184 29.2 454 28.9 .917
ypertension 533 84.6 1257 80.3 .018
AD 222 35.2 471 30.1 .019
yperlipidemia 358 56.8 893 57.0 .962
AD 125 19.8 263 16.8 .095
ymptomatic disease 187 29.7 497 31.7 .359
ontralateral occlusion 44 6.9 119 7.6 .654
n statin 245 38.9 580 37.0 .378
omplex plaque 248 39.4 558 35.6 .117
AS 332 52.7 748 47.8 .038
AD, Coronary artery disease; CAS, carotid artery stenting; PAD, periph-
ral artery disease; SD, standard deviation.se of statin was significantly associated with decreased risk
d
a
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January 201282 Parlani et al(OR, 0.37; 95% CI, .15-.92). When the use of insulin was
added to the model, insulin was borderline associated with
stroke and death rates (OR, 2.27; 95% CI, 1.00-5.13; P 
Table II. Baseline characteristics in diabetics vs nondiabet
Characteristic
Carotid stenting (n  1080)
Diabetes
(n  332)
Nondiabetes
(n  748)
n % n %
Age, years SD 70.31  7.18 72.09  75
Females 90 27.1 223 29.8
Hypertension 288 86.7 615 82.2
CAD 130 39.2 267 35.7
Hyperlipidemia 208 62.7 463 61.9
PAD 58 17.5 89 11.9
Symptomatic disease 77 23.2 191 25.5
Contralateral occlusion 23 6.9 59 7.9
On insulin 73 22.0 — —
On statin 145 43.7 319 42.6
On clopidogrelb 244 73.5 577 77.2
Complex plaque 110 33.1 228 30.5
Open cell stent 99 29.9 215 28.9
General anesthesiaa — — — —
CAD, Coronary artery disease; PAD, peripheral artery disease; SD, standard
aOnly for patients with carotid endarterectomy: 594 general anesthesia, 522
bOnly for patients with carotid stenting.
Fig 1. Perioperative outcome after carotid revascul.05). pTo address the potential differences in techniques and
etails affecting perioperative primary outcome, multivari-
te analysis was repeated separately for CEA and CAS
y procedure
P value
Carotid endarterectomy (n  1116)
P value
Diabetes
(n  298)
Nondiabetes
(n  818)
n % n %
.0001 69.99  7.08 71.45  7.88 .003
.38 94 31.5 231 28.2 .30
.75 245 82.2 642 78.5 .18
.30 92 31.0 204 24.9 .046
.84 150 50.3 430 52.6 .54
.02 67 22.6 174 21.3 .68
.45 110 36.9 306 37.4 .89
.62 21 7.0 60 7.3 1.00
— 77 25.8 — — —
.79 100 35.2 261 33.0 .51
.19 — — — — —
.39 138 46.9 330 41.1 .09
.77 – — — — —
— 160 53.7 434 53.1 .89
tion.
egional anesthesia.
ion in 630 diabetic and 1566 nondiabetic patients.ics b
deviarocedures.
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Volume 55, Number 1 Parlani et al 83For the 1116 CEA population, the only variable
retained in the last step of multivariate model as signifi-
cant independent predictor of perioperative higher
stroke and death rate was the presence of diabetes: OR,
2.83; 95% CI, 1.05-7.60; P  .04. When insulin was
added to the model, it was significantly associated with
outcome but 95% CI widened (OR, 7.55; 95% CI,
2.50-22.87; P  .0001).
For the 1080 CAS procedures, the use of statin remains
the only variable to be significantly associated with about
threefold decreased risk of perioperative stroke and death:
OR, 0.34; 95% CI, .14-.85; P  .021. Neither diabetes
(P  .47) nor insulin (P  .62) was associated with peri-
operative primary outcome.
Late outcomes. Mean follow-up was 47.23  28.5
months (from 1 to 123.4 months). During the observation
Table III. Univariate analysis on perioperative stroke and
Events %
Treatment
CAS 2.8
CEA 2.1
Diabetes
Yes 2.7
No 2.3
Insulin treatment
Yes 4.7
No 2.2
Symptoms
Yes 3.5
No 1.9
Female gender
Yes 2.5
No 2.4
Hypertension
Yes 2.6
No 1.7
CAD
Yes 2.3
No 2.5
PAD
Yes 1.8
No 2.5
Contralateral occlusion
Yes 3.1
No 2.4
Complex plaque
Yes 2.9
No 2.2
General anesthesiaa
Yes 2.9
No 1.1
Statins treatment
Yes 1.7
No 2.4
ASA treatment
Yes 2.6
No 3.0
ASA, Acetylsalicylic acid; CAD, coronary artery disease; CAS, carotid artery
PAD, peripheral artery disease.
aOnly in 1116 patients with carotid endarterectomy: 17/594 general anesthperiod, 321 patients died and 59 ischemic strokes were iecorded. In addition, 10 cerebral hemorrhages (1 nonfa-
al) occurred.
Six-year survival rates from any cause mortality were
6.0% in diabetic and 80.8% in nondiabetic (P  .153)
opulations (Fig 2).
Freedom from late stroke at 6 years rated 96.8% in
iabetics vs 95.4% in nondiabetics (P  .904; Fig 3).
During follow-up, recurrent stenosis of 50% or more
as detected in 80 patients (24 diabetics and 56 nondia-
etics) without significant difference in Kaplan-Meier esti-
ates at 6 years between diabetic and nondiabetic patients
ccording to log-rank test: 4.6% vs 4.2%; P .558 (Fig 4).
ive recurrent stenoses occurred in patients who experi-
nced late strokes.
There were no significant differences between diabetic
nd nondiabetic populations for each CAS or CEA subgroup
h in 2196 carotid procedures
OR 95% CI P value
1.358 0.78-2.35 .330
1.179 0.65-2.11 .645
2.128 0.94-4.79 .088
1.860 1.07-3.21 .034
1.057 0.58-1.91 .879
1.503 0.67-3.35 .374
0.936 0.51-1.69 .882
0.703 0.31-1.57 .469
1.309 0.51-3.33 .591
1.313 0.75-2.27 .388
2.534 0.99-6.47 .056
0.7 0.37-1.31 .288
0.853 0.34-2.12 .807
ng; CEA, carotid endarterectomy; CI, confidence interval; OR, odds ratio;
6/522 locoregional anesthesia.deat
stentin Kaplan-Meier estimates of survival (for CAS 81.7% vs
0
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January 201284 Parlani et al87.5%, P .12; for CEA 79.4% vs 82.8%, P .44), freedom
from late ischemic stroke (for CAS 96.0% vs 95.8%, P .13;
for CEA 97.2% vs 95.6%, P  .48), and from restenosis (for
CAS 95.6% vs 96.0%, P .73; for CEA 94.9% vs 96.8%, P
.66) rates at 5 years (due to small numbers in subgroup
analyses, curves were trimmed at 5 years).
Cox regression analysis after adjusting for potential
confounders with backwards elimination, demonstrated
that diabetes was associated with 6-year mortality (hazard
ratio [HR], 1.37; 95% CI, 1.07-1.74; P  .011). In addi-
tion, age (HR, 1.08; 95% CI, 1.06-1.10; P  .0001),
symptomatic stenosis (HR, 1.34; 95% CI, 1.07-1.68; P 
.012), coronary disease (HR, 1.40; 95%CI, 1.12-1.76; P
.004), and peripheral artery disease (HR, 1.52; 95% CI,
1.18-1.96; P  .001) were significant positive predictors
while female gender (HR, 0.69; 95% CI, .52-.91; P 
.008) and use of statins (HR, 0.51; 95% CI, .39-.66; P 
.0001) were negative predictors of death.
Age (HR, 1.08; 95% CI, 1.04-1.12; P  .0001) and
symptomatic disease (HR, 1.99; 95% CI, 1.19-3.34; P 
.009), but not diabetes (HR, 1.10; P .741), were positive
Table IV. Univariate analysis on perioperative stroke and
Carotid stenting (n  1080)
Events % OR 95% CI
Diabetes
Yes 2.1 0.68 0.3-1.6
No 3.1
On insulin
Yes 2.7 0.98 0.2-4.2
No 2.8
Female
Yes 2.2 0.74 0.3-1.7
No 3.0
Symptoms
Yes 4.5 2.07 0.9-4.3
No 2.2
Hypertension
Yes 2.7 0.77 0.3-1.9
No 3.4
CAD
Yes 2.5 0.86 0.4-1.8
No 2.9
PAD
Yes 2.7 0.98 0.3-2.8
No 2.8
Occlusion contr.
Yes 6.1 2.52 0.9-6.7
No 2.5
Complex plaque
Yes 3.6 1.48 0.7-3.1
No 2.4
On statin
Yes 1.3 0.32 0.1-0.8
No 3.9
General anesthesia
Yes
No
ASA, Acetylsalicylic acid; CAD, coronary artery disease; CAS, carotid artery
PAD, peripheral artery disease.predictors while use of statins was a negative predictor (HR, ..21; 95% CI, 0.09-0.46; P  .0001) of late ischemic
troke.
Peripheral artery disease was the only factor positively
ssociated with the incidence of restenosis (HR, 1.85; 95%
I, 1.13-3.02; P  .014) according to Cox analysis that
ailed to show any significant interaction with diabetes
HR, 1.12; P  .66).
Similar diabetes-related associations with late outcomes
ere found in models stratified by CAS or CEA procedure:
iabetes was confirmed a predictor of late death (HR, 1.63;
5% CI, 1.04-2.54; P .032) in CAS and, with borderline
ignificance, in CEA (HR, 1.333; 95% CI, .99-1.79; P 
055). There were no significant associations between dia-
etes and late stroke or restenosis after each of the two
rocedures.
ISCUSSION
Patients with diabetes and severe carotid stenosis share
imilar periprocedural stroke and death risks of nondiabetic
atients when carotid stenting is applied for treatment
perioperative stroke and death rate: 2.7% vs 2.3%; P 
by procedure
Carotid endarterectomy (n  1116)
P Events % OR 95% CI P
.42 3.4 2.1 0.9-4.3 .09
1.6
.00 6.5 3.93 1.4-10.9 .017
1.7
.54 2.8 1.58 0.7-3.6 .35
1.8
.056 2.9 1.86 0.8-4.2 .19
1.6
.61 2.5 5.79 0.7-43.2 .06
0.4
.85 2.0 0.97 0.4-2.5 1.00
2.1
.00 1.2 0.53 0.2-1.8 .44
2.3
.07 0 — — .4
2.2
.32 2.4 1.23 0.5-2.8 .67
1.9
.01 2.2 1.99 0.7-5.3 .18
1.1
2.9 2.53 0.9-6.4 .056
1.1
ng; CEA, carotid endarterectomy; CI, confidence interval; OR, odds ratio;death
1
164). However, with a surgical approach to treat carotid
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Volume 55, Number 1 Parlani et al 85stenosis, the perioperative risk of stroke and death might be
threefold higher (OR, 2.83; 95%CI, 1.05-7.61; P .04) in
diabetic patients. After perioperative period, the rate of
stroke is 5% at 6 years with both procedures confirming
that the efficacy of carotid revascularization in stroke pre-
vention may persist in the long term also in diabetic set-
tings. These data might suggest the presence of diabetes as
an indicator to identify subgroups of patients better suited
for CAS than for CEA due to the proportionally higher
surgical risks of the CEA procedure.
Diabetes mellitus is one of the most common and
disabling diseases in western countries affecting about one
of every five adults aged60 years with a strong cardiovas-
cular burden.12-14 Epidemiologic studies have confirmed
that diabetes independently increases risks of ischemic
stroke (with relative risk ranging from 1.8-fold to sixfold)
and that stroke functional outcome is worse and stroke-
related mortality is higher in diabetic patients.15-18 There-
fore, it is expected that the benefit of stroke prevention
measures, as carotid revascularization in those with severe
carotid stenosis, might be higher in these patients. Never-
Fig 2. Six-year Kaplan-Meier estimates of survival in diabtheless, surgical carotid intervention conveys a periopera- tive burden that could offset the long-term benefit. This
ikely does not apply to carotid stenting procedure.
Very few studies have analyzed the role of diabetes in
AS population.19 Siewiorek et al, who specifically ana-
yzed the association of clinical variables and 30-day out-
omes in 203 CAS procedures, found that diabetes (OR,
.8; 95% CI, 1.0-7.6; P  .04) and prior CEA (OR, 1.8;
5%CI, 1.1-3.1; P .03) were significantly associated with
dverse outcome in terms of increased combined rate of
troke, TIA, and death within 30 days.19 Nevertheless, the
nclusion of minor neurologic complications (TIA) influ-
nced significance for the combined outcome. Indeed,
ates of stroke alone (P .28) or mortality alone (P .41)
ere not significantly higher in diabetic patients.19 Accord-
ng to the pooled analysis of outcomes from randomized
linical trials (RCTs) (International Carotid Stenting Study
ICSS], Endarterectomy Versus Angioplasty in Patients
ith Symptomatic Severe Carotid Stenosis [EVA-3S],
tent-Protected Angioplasty versus Carotid Endarterec-
omy [SPACE]) comparing CAS vs CEA in 3454 symp-
d nondiabetic populations after carotid revascularization.omatic patients, CAS was shown to increase perioperative
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population, but not in the diabetic subgroup (OR, 1.21;
95% CI, .78-1.88).20 Specifically, cumulative stroke and
death risks within 120 days were 9.8% in diabetics vs 8.5% in
nondiabetics in the CAS population and 8.0% in diabetics
vs 5.1% in nondiabetics in the CEA population.20 These
RCT data agree with our findings not supporting higher
perioperative risk in diabetic CAS populations.
A number of differences in techniques and approaches
between procedures could explain the different periopera-
tive exposure risk of diabetic patients during stenting vs
during CEA.21 The more diffuse intracranial small vessel
disease associated with lower clamping tolerance in the
diabetic population may be a factor, another could be the
use of general anesthesia or the overall higher surgical stress
during open surgery that can influence the adverse out-
come of surgery in diabetics. Nevertheless, the true reasons
and mechanisms for different perioperative risks between
CAS and CEA diabetic patients remain largely unsettled
and future studies should be specifically conducted to pro-
Fig 3. Six-year Kaplan-Meier estimates of freedom from
carotid revascularization.vide further insight in this direction. aOther literature data analyzing medical management
f diabetes in CEA supported an increased operative risk
or insulin takers, to some extent confirmed by our
ata.15,22,23 The need for insulin might be associated
ith more than sevenfold increased risks of perioperative
troke and deaths after CEA: 6.5% vs 1.7% in patients
ith and without insulin, respectively; (OR, 7.55; 95%
I, 2.50-22.87; P  .0001, multivariate analysis). This
ay suggest that a more advanced diabetic disease, or a
ifferent metabolic status requiring more aggressive gly-
emic control in diabetic patients requiring insulin could
ead to higher ischemic events and mortality. However,
ur data may be unbalanced and underpowered to prove
ifferences between treatments and should be inter-
reted with caution. Nevertheless, other studies also
eported conflicting data on the role of insulin-depen-
ent treatment and CEA risk.3,23 Irrespective of the
verall effect, the mechanisms of the suggested insulin-
ncreased risks of CEA are unknown.
Despite the lower life expectancy due to increased
mic stroke in diabetic and nondiabetic populations afterischell-cause mortality (6-year survival 76.0% vs 80.8%), in the
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did not perform worse in terms of increased stroke or
restenosis risks at 6 years. These data confirm the durability
of the carotid repair (whichever the treatment applied) and
the efficacy of stroke prevention of carotid revasculariza-
tion. Our long-term results are of relevance especially for
the CAS group since the durability of the procedure is still
questioned. According to our findings, low stroke rates
(4%) and restenosis rates (4.4%) can be achieved with CAS
after 5 years also in subgroups of patients with higher
cardiovascular mortality and morbidity such as diabetic
patients.
The presence of diabetes might both increase neointi-
mal hyperplasia and accelerate the growth of new carotid
plaques at the site of arterial injury, thereby implying an
increased restenosis risk after revascularization.3,24 How-
ever, this hypothesis has not been supported by large evi-
dence. Our study, as well as others in the literature,2,25,26
confirmed that diabetic patients have similar restenosis rates
compared with nondiabetic patients, whichever treatment
Fig 4. Six-year Kaplan-Meier estimates of freedom fro
carotid revascularization.was applied to treat carotid stenosis. eStudy limitations. This study is retrospective in na-
ure and clinical decision-making was based on physician-
uided indications and not on a randomization list.
We did not perform biochemical assessments to evaluate
lycemic or metabolic control in diabetic and nondiabetic
roups, and patients’ adherence to prescribed therapy was not
upervised. Subgroup analyses (on-insulin, general anesthesia,
AS) might be underpowered to provide reliable data.
ONCLUSIONS
Diabetes is prevalent among patients with carotid ste-
osis affecting about almost one third of those undergoing
arotid revascularization (28.7%). Diabetic patients under-
oing CAS are not at greater risk of perioperative morbidity
s well as stroke and restenosis at 6 years after the procedure
ompared with patients without diabetes. Therefore, long-
erm stroke prevention with carotid revascularization may
e fulfilled also in the presence of diabetes. Nevertheless,
iabetes may be considered a significant risk factor during
he perioperative period for patients undergoing carotid
stenosis in diabetic and nondiabetic populations afterm rendarterectomy. This may help in selecting the appropriate
11
1
1
1
1
1
1
2
2
2
2
2
2
2
JOURNAL OF VASCULAR SURGERY
January 201288 Parlani et altechnique for carotid revascularization in patients best
suited for type of procedure.
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DrChristos Liapis (Athens, Greece). Excellent paper. I have one
question and one comment. Did you analyze separately patients with
typeA and typeBdiabetes? Andmy comment is that only 35%of your
patients in both groups were on statins, yet, the main statisticalDrEnrico Cieri.We did not analyze specifically type A and type
diabetes, but our aged population was mainly affected by type B
iabetes independently of their current use of insulin or oral hypogly-
emic agents. But I am sorry. I have no data about type A and type B
iabetes. And for sure, statins is a very protective factor for both the
rocedures (endarterectomy and stenting). I agree absolutely with you.
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Volume 55, Number 1 Parlani et al 89Dr John Ricotta (Washington, DC). Do you have data on
hemoglobin A1C levels in the two patient groups that might give
us an idea of whether they were comparable at the time of surgery?
Do you have any data on that?
DrCieri.No, I am sorry, because the study was a retrospective
analysis of a prospective database and we did not record this data.
DrRicotta.Do you think that the fact that there seemed to be
a greater burden of atherosclerosis in the endarterectomy patients,
for example, they had more peripheral vascular disease and more
tortuous arch anatomy, do you think that might influence your
results in any way?
Dr Cieri. I really think that diabetes is in itself a marker of a
poor systemic condition, and several studies are analyzing the
effect of diabetes or its medications (eg, insulin) on the inflamma-
tory process of atherosclerosis. So, I think that the surgical stress in
carotid endarterectomy might be a key point in diabetic patients’
risk and this, more than arch or vessel anatomy, might have
influenced our results.
e
aDr Jean-Baptiste Ricco (Poitiers, France). Did you do any
ropensity analysis between carotid stenting vs carotid endarterec-
omy to make sure that the observed effect is not due to differences
n participants in the two groups rather than or in addition to the
ntervention?
Dr Cieri. No, we did not perform propensity analysis. Really,
he aim of our study was not to compare carotid endarterectomy
ith carotid stenting, but to see whether diabetes could affect in
arotid revascularization, whichever the technique used. So we did
ot perform a propensity adjustment of patients for carotid endar-
erectomy vs carotid stenting.
Dr Robert Zwolak (Lebanon, NH). Did you have equal
ercentages of symptomatic and asymptomatic patients in the
ndarterectomy and carotid stenting groups?
Dr Cieri. Yes. No statistical difference was found in distribu-
ion of symptomatic and asymptomatic patients between carotid
ndarterectomy and carotid stenting group or between diabetic
nd nondiabetic patients.
